Levamlodipine/Bisoprolol

左旋氨氯地平/比索洛尔

Report date: 2025/04/28 09:43:40

Base Information

Drug NameLevamlodipine/Bisoprolol
Drug Alias NameLevamlodipine-Bisoprolol左旋氨氯地平•比索洛尔Levamlodipine•Bisoprolol左旋氨氯地平和比索洛尔Levamlodipine and Bisoprolol +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVoltage-gated L-type calcium channel blockersBeta-1 adrenergic receptor antagonists
TargetsVoltage-gated L-type calcium channelBeta-1 adrenergic receptor
Therapy Area/IndicationsEssential HypertensionHypertension
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsYes Bisoprolol FumarateLevamlodipine Maleate
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesShihuida Pharmaceutical Group (Jilin) ​​Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShihuida Pharmaceutical Group (Jilin) ​​Co LtdJiangxi Shimei Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsEssential HypertensionHypertension
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A